Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

By K. Hotta, T. Funahashi, Y. Arita, Masahiko Takahashi, M. Matsuda, Y. Okamoto, H. Iwahashi, H. Kuriyama, N. Ouchi, K. Maeda and 11 more. Arteriosclerosis, Thrombosis and Vascular Biology, 2000

3,308 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrine and Autonomic Systems, Epidemiology

View Paper: https://www.semanticscholar.org/paper/5f75068a6c5448597a8a79415d879b54ee7fff3c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Endocrine and Autonomic Systems

In Epidemiology

Citations in the corpus

Hypoxia and adipose tissue function and dysfunction in obesity. (2013, background): “The expression and release of a number of inflammation-related adipokines rise markedly in obesity (80, 158, 198), the notable exception being adiponectin, the production of which falls (2, 85).”
Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation (2007, background): “Plasma adiponectin levels are low in obesity and type 2 diabetes (11,12).”
The mechanisms of action of PPARs. (2002, background): “Therefore, as depicted in Figure 3, mediators of the beneficial metabolic effects of PPARγ agonists on distant tissues (muscle and liver) are likely to involve a combined effect to (a) enhance insulin-mediated adipose tissue uptake, storage (and potentially catabolism) of free fatty acids (88); (b) ”
Adiponectin: A novel adipokine linking adipocytes and vascular function. (2004, neutral): “Adiponectin levels are also significantly lower in patients with coronary artery disease than in matched control subjects, suggesting a possible association of reduced adiponectin in vasculopathic states (18, 19).”
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action (2001, background): “Serum levels of Acrp30 are significantly decreased in both obesity and type 2 diabetes, indicating a possible metabolic role or relationship to insulin resistanc”
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, background): “Serum levels of adiponectin decrease with obesity and are positively associated with insulin sensitivity [22,23].”
Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. (2003, background): “Even though circulating levels of adiponectin have been found to be higher in women compared with men, the association between adiponectin and measures of adiposity, type 2 diabetes, or cardiovascular disease displays no gender difference (1, 21).”
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. (2003, background): “Plasma adiponectin concentrations are lower in patients with diabetes (13) and ischemic heart disease (14).”
Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. (2002, background): “Plasma concentrations of adiponectin correlate inversely with BMI (19) and are reduced in patients with type 2 diabetes compared with those in BMI-matched subjects (10).”
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. (2015, background): “014 Professeur Calmette, BP245, 59019 LILLE Cédex, France. n; FA, fatty acid; APR, acute phase response; NASH, non-alcoholic steatohepatitis; lipoprotein; HDL-C, high density lipoprotein cholesterol; SPPARM, selective PPAR DNA binding domain; PPRE, PPAR response element; DR-1, direct repeat-1; RXR, ”